# US 2024/0199614 A1 · Macrocyclic egfr inhibitors for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199614 A1
- Document ID: US20240199614A1
- Status: Published application
- Kind: A1
- Application number: 18/552,302
- Filed: 2022-03-25
- Published: 2024-06-20
- Earliest claimed: 2021-03-26
- Assignees: Theseus Pharmaceuticals, Inc.
- Applicants: Theseus Pharmaceuticals, Inc.
- Inventors: Wei-Sheng HUANG; William C. SHAKESPEARE; Charles J. EYERMANN; David C. DALGARNO
- Web page: https://patentgrep.com/patent/US20240199614A1

## CPC

- C07D 471/22: in which the condensed systems contains four or more hetero rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/499: Spiro-condensed pyrazines or piperazines
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 35/00: Antineoplastic agents
- C07D 498/22: in which the condensed system contains four or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein
A1 is independently phenylene or 5- or 6-membered heteroarylene;
A2 is independently phenyl, naphthyl, or a 5- to 13-membered heteroaryl;
X1 is independently O or X1A;
X1A is a covalent bond, S, NR4, C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene;
each of X2 and X3 is independently N or CR1B;
L1 is independently a covalent bond or C1-6 alkylene;
L2 is independently a covalent bond, C2-6 alkenylene, C2-6 alkynylene, C3-6 cycloalkylene, 3- to 10-membered heterocyclylene, phenylene, or 5- or 6-membered heteroarylene;
each R1A and R1B is independently H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR6R7, C(O)R8, CO2R8, C(O)NR6R7, NR9C(O)R8, NR9CO2R8, NR9C(O)NR6R7, or R10;
each R2 and R3, when present, is independently OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR6R7, C(O)R8, CO2R′, C(O)NR6R7, NR9C(O)R8, NR9CO2R8, NR9C(O)NR6R7, R10, OR10, CH2R10, CH2CH2R10, OCH2R10, or OCH2CH2R10;
each R4 is independently H, a N-protecting group, or C1-6 alkyl;
R5 is hydrogen;
each R6, R7, and R9 is independently H or C1-6 alkyl; or R6 and R7, together with the nitrogen atom to which they are attached, form a 3- to 10-membered heterocyclyl, or R6 and R9, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl;
R8 is independently C1-6 aliphatic, C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl, or R8 and R9, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl;
R10 is independently C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl;
each of n and o is independently 0, 1, or 2; and
wherein X1 is O, and both of X2 and X3 are not N, then A2 is naphthyl or a bicyclic 8- to 12-membered heteroaryl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein at least one of X2 and X3 is N.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, having a structure according to Formula (II),
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1, 2)

The compound of claim 1 or 2, having a structure according to Formula (III),
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1, having a structure according to Formula (IV),
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein each R1B is H.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein X1 is XIA.

### Claim 8 (depends on 7)

The compound of claim 7, having a structure according to Formula (V),
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The compound of claim 1, having a structure according to Formula (VI),
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The compound of claim 9, having a structure according to Formula (VI-1),
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 9)

The compound of claim 9, having a structure according to Formula (VI-2),
or a pharmaceutically acceptable salt thereof, wherein
each R11 is independently OH, CN, halogen, C1-6 alkyl, or C1-6 alkoxy; and
m is 0, 1, or 2.

### Claim 12 (depends on 9)

The compound of claim 9, having a structure according to Formula (VI-3),
or a pharmaceutically acceptable salt thereof, wherein
each R11 is independently OH, oxo, CN, halogen, C1-6 alkyl, or C1-6 alkoxy;
m is 0, 1, or 2; and
p is 0, 1, 2, or 3.

### Claim 13 (depends on 11, 12)

The compound of claim 11 or 12, wherein X1A is a covalent bond or C1-6 alkylene.

### Claim 14 (depends on 9)

The compound of claim 9, having a structure according to Formula (VI-4),
or a pharmaceutically acceptable salt thereof, wherein
X1A is independently a covalent bond or C1-6 alkylene; and
each R12A and R12B is independently H or C1-6 alkyl, or R12A and R12B combine to form a cyclopentene or cyclohexene.

### Claim 15 (depends on 9)

The compound of claim 9, having a structure according to Formula (VI-5),
or a pharmaceutically acceptable salt thereof, wherein
X1A is a covalent bond or C1-6 alkylene; and
L1 is C1-6 alkylene.

### Claim 16 (depends on 9, 10, 11, 12, 13, 14, 15)

The compound of any one of claims 9-15, wherein R2 is CH3.

### Claim 17 (depends on 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 9-16, wherein L1 is linear or branched C1-6 alkylene, and wherein said alkylene is unsubstituted or comprises a —OH group.

### Claim 18 (depends on 1)

The compound of claim 1, having a structure according to Formula (VII),
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

The compound of claim 1, having a structure according to Formula (VIII),
or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 18, 19)

The compound of any one of claims 1-9 and 18-19, wherein A2 is a monocyclic 5-to-6-membered heteroaryl.

### Claim 21 (depends on 20)

The compound of claim 20, wherein A2 is pyridyl, pyrimidyl, pyrazolyl, thiazolyl, oxazolyl, or imidazolyl, and wherein A2 is optionally substituted by a methyl, halogen, or CN.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 18, 19)

The compound of any one of claims 1-9 and 18-19, wherein A2 is phenyl, naphthyl, or a bicyclic 8- to 12-membered heteroaryl.

### Claim 23 (depends on 22)

The compound of claim 22, wherein A2 is a nitrogen-containing, bicyclic 8- to 12-membered heteroaryl that is indolyl, benzimidazolyl, indazolyl, isoindolyl, pyrrolopyrimidyl, pyrrolopyridinyl, pyrazolopyrimidyl, pyrazolopyridinyl, benzotriazolyl, quinolyl, or isoquinolyl.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 18, 19, 20, 21, 22, 23)

The compound of any one of claims 1-10 and 18-23, wherein X1 is X1A.

### Claim 25 (depends on 24)

The compound of claim 24, wherein X1A is a covalent bond.

### Claim 26 (depends on 24)

The compound of claim 24, wherein X1A is S or NR4.

### Claim 27 (depends on 24)

The compound of claim 24, wherein X1A is C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 18, 19, 20, 21, 22, 23)

The compound of any one of claims 1-10 and 18-23, wherein X1 is O.

### Claim 29 (depends on 1, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 1 and 8-28, wherein X2 and/or X3 is N.

### Claim 30 (depends on 1, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 1 and 8-28, wherein each of X2 and X3 is CR1B.

### Claim 31 (depends on 30)

The compound of claim 30, wherein each of X2 and X3 is CH.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of any one of claims 1-16 and 18-31, wherein U is a covalent bond, unsubstituted branched C1-6 alkylene, or linear C1-6 alkylene optionally comprising a —OH substituent.

### Claim 33 (depends on 32)

The compound of claim 32, wherein L is a covalent bond.

### Claim 34 (depends on 32)

The compound of claim 32, wherein L1 is unsubstituted branched C1-6 alkylene or linear C1-6 alkylene optionally comprising a —OH substituent.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The compound of any one of claims 1-10 and 18-32, wherein L2 is C2-6 alkenylene or C2-6 alkynylene.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The compound of any one of claims 1-10 and 18-32, wherein L2 is C3-6 cycloalkylene or 3- to 10-membered heterocyclylene.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The compound of any one of claims 1-10 and 18-32, wherein L2 is phenylene, or 5- or 6-membered heteroarylene.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The compound of any one of claims 1-10 and 18-32, wherein L2 is a covalent bond.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein:
X1 is X1A, wherein X1A is a covalent bond, C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene;
L1 is independently a covalent bond or C1-6 alkylene;
L2 is independently a covalent bond, C2-6 alkenylene, C2-6 alkynylene;
C3-6 cycloalkylene, 3- to 10-membered heterocyclylene, phenylene, or 5- or 6-membered heteroarylene; and
wherein at least one of XA, L1, and L2 is a covalent bond.

### Claim 40 (depends on 39)

The compound of claim 39, wherein:
one X1A and L1 is a covalent bond and the other is C1-6 alkylene; and
L2 is a covalent bond.

### Claim 41 (depends on 39)

The compound of claim 39, wherein each of L1 and L2 is a covalent bond.

### Claim 42 (depends on 39)

The compound of claim 39, wherein each of X1A and L2 is a covalent bond.

### Claim 43 (depends on 39)

The compound of claim 39, wherein each of X1A and L1 is a covalent bond.

### Claim 44 (depends on 1)

The compound of claim 1, wherein said compound has a structure according to Formula (IX),
or a pharmaceutically acceptable salt thereof, wherein
L1 is C1-C6 alkylene optionally substituted by 1, 2, or 3 R13;
each R13 is independently unsubstituted C1-C3 alkyl; and
R1A is independently unsubstituted C1-C6 alkyl or C1-C6 haloalkyl.

### Claim 45 (depends on 1)

The compound of claim 1, wherein said compound has a structure according to Formula (X),
or a pharmaceutically acceptable salt thereof, wherein
L1 is C1-C6 alkylene optionally substituted by 1, 2, or 3 R13;
each R13 is independently unsubstituted C1-C3 alkyl; and
R1A is independently unsubstituted C1-C6 alkyl or C1-C6 haloalkyl.

### Claim 46 (depends on 1)

The compound of claim 1, wherein said compound has a structure according to Formula (XI),
or a pharmaceutically acceptable salt thereof, wherein
L1 is C1-C6 alkylene optionally substituted by 1, 2, or 3 R13;
each R13 is independently unsubstituted C1-C3 alkyl; and
R1A is independently unsubstituted C1-C6 alkyl or C1-C6 haloalkyl.

### Claim 47 (depends on 44, 45, 46)

The compound of any one of claims 44-46, wherein L1 is selected from the following group of substructures:
wherein a carbon marked by an asterisk (*) is racemic or has the (R)- or (S)-stereochemistry.

### Claim 48 (depends on 44, 47)

The compound of claim 44 or 47, wherein said compound has a structure according to:
or a pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 44, 47)

The compound of claim 44 or 47, wherein said compound has a structure according to:
or a pharmaceutically acceptable salt thereof, wherein n is 1, 2, or 3.

### Claim 50 (depends on 44, 47)

The compound of claim 44 or 47, wherein said compound has a structure according to:
or a pharmaceutically acceptable salt thereof.

### Claim 51 (depends on 1)

The compound of claim 1, wherein said compound has a structure according to Formula (XII),
or a pharmaceutically acceptable salt thereof, wherein
R1A is independently unsubstituted C1-C6 alkyl or C1-C6 haloalkyl.

### Claim 52 (depends on 1)

The compound of claim 1, wherein said compound has a structure according to Formula (XIII),
or a pharmaceutically acceptable salt thereof, wherein
L1 is C1-C3 alkylene optionally substituted by 1 or 2 R13;
each R13 is independently unsubstituted C1-C3 alkyl; and
R1A is independently unsubstituted C1-C6 alkyl or C1-C6 haloalkyl.

### Claim 53 (depends on 52)

The compound of claim 52, wherein L is —CH2— or —CH2CHCH3—.

### Claim 54 (depends on 1)

The compound of claim 1, wherein said compound has a structure according to Formula (XIV),
or a pharmaceutically acceptable salt thereof, wherein
L1 is C2-C4 alkylene optionally substituted by 1 or 2 R13;
each R13 is independently unsubstituted C1-C3 alkyl; and
R1A is independently unsubstituted C1-C6 alkyl or C1-C6 haloalkyl.

### Claim 55 (depends on 54)

The compound of claim 54, wherein L1 is —(CH2)3— or —(CH2)4—.

### Claim 56 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The compound of any one of claims 44-55, wherein R1A is CH3, CH2F, CHF2, or CF3.

### Claim 57 (depends on 56)

The compound of claim 56, wherein R1A is CH3.

### Claim 58 (depends on 1, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 1 and 44-57, wherein R3 is halogen;
NR6R7, wherein R6 and R7, together with the nitrogen atom to which they are attached, form a 5- to 7-membered heterocyclyl;
NR6R7, wherein each R6 and R7 is independently C1-C6 alkyl;
phenyl;
pyridyl;
C(O)R8, wherein R1 is a 5- to 6-membered nitrogen-containing heterocyclyl;
R10, wherein R10 is a 5- to 6-membered nitrogen-containing heterocyclyl;
OR10, wherein R10 is a 5- to 6-membered nitrogen-containing heterocyclyl;
CH2R10, wherein R10 is a 5- to 6-membered nitrogen-containing heterocyclyl;
CH2CH2R10, wherein R10 is a 5- to 6-membered nitrogen-containing heterocyclyl; or
OCH2CH2R10, wherein R10 is a 5- to 6-membered nitrogen-containing heterocyclyl.

### Claim 59 (depends on 58)

The compound of claim 58, wherein R3 is halogen.

### Claim 60 (depends on 58)

The compound of claim 58, wherein R3 is NR6R7, wherein R6 and R7, together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclyl.

### Claim 61 (depends on 60)

The compound of claim 60, wherein R3 is unsubstituted or substituted pyrrolidine, morpholine, piperidine, or piperazine.

### Claim 62 (depends on 58)

The compound of claim 58, wherein R3 is C(O)R8, wherein R8 is unsubstituted or substituted pyrrolidine, morpholine, piperidine, or piperazine.

### Claim 63 (depends on 58)

The compound of claim 58, wherein R3 is unsubstituted or substituted phenyl or pyridyl.

### Claim 64 (depends on 58)

The compound of claim 58, wherein R3 is R10, OR10, CH2R10, CH2CH2R10, or OCH2CH2R10, wherein R10 is unsubstituted or substituted pyrrolidine, morpholine, piperidine, or piperazine.

### Claim 65 (depends on 58)

The compound of claim 58, wherein R3 is selected from the group consisting of.

### Claim 66 (depends on 1)

The compound of claim 1, selected from the group consisting of Compounds (1)-(71), or a pharmaceutically acceptable salt thereof.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

A pharmaceutical composition comprising a compound according to any one of claims 1-66, or a pharmaceutically acceptable salt thereof.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

A method of treating cancer comprising administering to a human in need thereof an effective amount of a compound according to any one of claims 1-66 or a pharmaceutically acceptable salt thereof in a pharmaceutical composition.

### Claim 69 (depends on 68)

The method of claim 68, wherein said cancer is a lung cancer.

### Claim 70 (depends on 68, 69)

The method of claim 68 or 69, wherein said cancer is non-small cell lung cancer.

### Claim 71 (depends on 68, 69, 70)

The method ofany one of claims 68-70, wherein said cancer is an EGFR-driven cancer.

### Claim 72 (depends on 68, 69, 70, 71)

The method of any one of claims 68-71, wherein said cancer is characterized by an EGFR mutation.
